Inclusion and exclusion criteria.
Inclusion criteria

Written informed consent
Male or female patients aged ≥ 18 years Patients with physician-diagnosed ILD who fulfil at least one of the following criteria for PF-ILD within 24 months of screening despite treatment with unapproved medications used in clinical practice to treat ILD:
• Clinically significant decline in FVC % pred based on a relative decline of ≥ 10% • Marginal decline in FVC % pred based on a relative decline of ≥ 5 -< 10% combined with worsening respiratory symptoms • Marginal decline in FVC % pred based on a relative decline of ≥ 5 -< 10% combined with increasing extent of fibrotic changes on chest imaging • Worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging Changes attributable to comorbidities (eg infection, heart failure) must be excluded Unapproved medications used to treat ILD in clinical practice include, but are not limited to, corticosteroids, azathioprine, mycophenolate mofetil, n-acetylcysteine, rituximab, cyclophosphamide, cyclosporine and tacrolimus Fibrosing lung disease on HRCT (performed within 12 months of screening and confirmed by central readers), defined as reticular abnormality with traction bronchiectasis with or without honeycombing, with disease extent of > 10%
For patients with underlying CTD: Stable CTD, defined as no initiation of new CTD therapy or withdrawal of CTD therapy within 6 weeks before screening DLCO corrected for haemoglobin ≥ 30% and < 80% of predicted normal at randomisation FVC ≥ 45% predicted at randomisation Peanut allergy
Other disease that may interfere with the testing procedures or (in the opinion of the investigator) with trial participation or may put the patient at risk when participating in the trial Life expectancy for disease other than ILD < 2.5 years (investigator's assessment)
Planned major surgical procedures
Women who are pregnant, nursing or who plan to become pregnant during the trial Women of childbearing potential not willing or able to use highly effective methods of birth control that result in a low failure rate of less than 1% per year (when used consistently and correctly) and one barrier method for 28 days before and 3 months after nintedanib administration Active alcohol or drug abuse (in the opinion of the investigator)
Patients not able to understand or follow trial procedures (including completion of self-administered questionnaires) without help Abbreviations: % pred, per cent predicted; ALAT, Latin American Thoracic Association; ALT, alanine transaminase; aPTT, activated partial thromboplastin time; AST, aspartate transaminase; ATS, American Thoracic Society; CTD, connective tissue disease; DLCO, diffusing capacity of the lungs for carbon monoxide; ERS, European Respiratory Society; FEV 1 , forced expiratory volume in 1 second; FVC, forced vital capacity; HRCT, high-resolution computed tomography; ILD, interstitial lung disease; INR, international normalised ratio; IPF, idiopathic pulmonary fibrosis; JRS, Japanese Respiratory Society; PF-ILD, progressive fibrosing interstitial lung disease; ULN, upper limit of normal. * = Results for these parameters at Visit 2 (randomisation) will only become available after randomisation; if they no longer satisfy the entry criteria, entry of the patient is at the discretion of the investigator. ** = Prophylactic low-dose heparin or heparin flush for maintenance of an indwelling intravenous device and prophylactic use of antiplatelet therapy are not prohibited.
Table S2
Power properties for varying treatment differences in the two co-primary populations.
Patients with HRCT with UIP-like fibrotic pattern only (co-primary)
Patients with other HRCT fibrotic patterns
Overall patient population (co-primary)
Scenario 1
Assumed treatment difference in absolute change in FVC in mL/year (SD) 100 (300) 75 (400) 
Scenario 3
Assumed treatment difference in absolute change in FVC in mL/year (SD)
75 (300) 75 (400) 75 (337) Individual test power 68.2% 73.4%
Overall power * 75.8% Abbreviations: FVC, forced vital capacity; HRCT, high-resolution computed tomography; IPF, idiopathic pulmonary fibrosis; PF-ILD, progressive fibrosing ILD; SD, standard deviation; UIP, usual interstitial pneumonia. * = The probability of concluding statistical significance for either of the co-primary populations.
For scenario planning, annual rates of decline in FVC of 150-200 mL/year and 120-150 mL/year have been assumed for PF-ILD patients with UIP-like HRCT pattern and for patients with other HRCT fibrotic patterns, respectively.
Based on the IPF data, in patients treated with nintedanib, an approximate 50% reduction in the annual rate of decline in FVC is expected. The treatment effect to detect is therefore in the range of 75-100 mL/year for the PF-ILD patients with UIP-like HRCT pattern and of 60-75 mL/year in the PF-ILD patients with other HRCT fibrotic patterns.
For patients with other HRCT fibrotic patterns, the variability is assumed to be larger than in IPF with a SD of 400 mL/year. For patients with UIP-like HRCT pattern, a more homogeneous group of patients, the variability is assumed to be the same as observed in IPF with a SD of 300 mL/year. Therefore, the proposed sample size of 300 patients randomised per treatment group, ie 600 patients in total, including 400 patients with UIPlike HRCT pattern, will provide adequate power to demonstrate a clinically important treatment benefit on the primary endpoint even in scenarios where the annual rate of decline in both co-primary patient populations is lower than observed for IPF patients in the Phase III IPF trials.
